Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach
Breast cancer is the most common malignancy among women. It is a complex condition with many subtypes based on the hormone receptor. The mammalian target of the rapamycin (mTOR) pathway regulates cell survival, metabolism, growth, and protein synthesis in response to upstream signals in both normal physiological and pathological situations, primarily in cancer. The objective of this study was to screen for a potential target to inhibit the mTOR using a variety of inhibitors derived from Cichorium intybus and to identify the one with the highest binding affinity for the receptor protein. Initially, AutoDock Vina was used to perform structure-based virtual screening, as protein-like interactions are critical in drug development. For the comparative analysis, 110 components of Cichorium intybus were employed and ten FDA-approved anticancer medicines, including everolimus, an mTOR inhibitor. Further, the drug-likeness and ADMET properties were investigated to evaluate the anti-breast cancer activity by applying Lipinski's rule of five to the selected molecules. The promising candidates were then subjected to three replica molecular dynamics simulations run for 100 ns, followed by binding free energy estimation using MM-GBSA. The data were analyzed using root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), and protein–ligand interactions to determine the stability of the protein–ligand complex. Based on the results, taraxerone (98) revealed optimum binding affinities with mTOR, followed by stigmasterol (110) and rutin (104), which compared favorably to the control compounds. Subsequently, bioactive compounds derived from Cichorium intybus may serve as lead molecules for developing potent and effective mTOR inhibitors to treat breast cancer. Graphical abstract.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Molecular diversity - 27(2022), 3 vom: 23. Juni, Seite 1141-1162 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rasul, Hezha O. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 |
|---|
| doi: |
10.1007/s11030-022-10475-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2143919298 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2143919298 | ||
| 003 | DE-627 | ||
| 005 | 20240118092414.0 | ||
| 007 | tu | ||
| 008 | 240118s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11030-022-10475-9 |2 doi | |
| 035 | |a (DE-627)OLC2143919298 | ||
| 035 | |a (DE-He213)s11030-022-10475-9-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 100 | 1 | |a Rasul, Hezha O. |e verfasserin |0 (orcid)0000-0001-5250-003X |4 aut | |
| 245 | 1 | 0 | |a Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 | ||
| 520 | |a Breast cancer is the most common malignancy among women. It is a complex condition with many subtypes based on the hormone receptor. The mammalian target of the rapamycin (mTOR) pathway regulates cell survival, metabolism, growth, and protein synthesis in response to upstream signals in both normal physiological and pathological situations, primarily in cancer. The objective of this study was to screen for a potential target to inhibit the mTOR using a variety of inhibitors derived from Cichorium intybus and to identify the one with the highest binding affinity for the receptor protein. Initially, AutoDock Vina was used to perform structure-based virtual screening, as protein-like interactions are critical in drug development. For the comparative analysis, 110 components of Cichorium intybus were employed and ten FDA-approved anticancer medicines, including everolimus, an mTOR inhibitor. Further, the drug-likeness and ADMET properties were investigated to evaluate the anti-breast cancer activity by applying Lipinski's rule of five to the selected molecules. The promising candidates were then subjected to three replica molecular dynamics simulations run for 100 ns, followed by binding free energy estimation using MM-GBSA. The data were analyzed using root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), and protein–ligand interactions to determine the stability of the protein–ligand complex. Based on the results, taraxerone (98) revealed optimum binding affinities with mTOR, followed by stigmasterol (110) and rutin (104), which compared favorably to the control compounds. Subsequently, bioactive compounds derived from Cichorium intybus may serve as lead molecules for developing potent and effective mTOR inhibitors to treat breast cancer. Graphical abstract | ||
| 650 | 4 | |a mTOR | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Molecular docking | |
| 650 | 4 | |a Molecular dynamic | |
| 650 | 4 | |a MM-GBSA | |
| 700 | 1 | |a Aziz, Bakhtyar K. |4 aut | |
| 700 | 1 | |a Ghafour, Dlzar D. |4 aut | |
| 700 | 1 | |a Kivrak, Arif |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular diversity |d Springer International Publishing, 1995 |g 27(2022), 3 vom: 23. Juni, Seite 1141-1162 |w (DE-627)225977672 |w (DE-600)1376507-3 |w (DE-576)9225977670 |x 1381-1991 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:3 |g day:23 |g month:06 |g pages:1141-1162 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11030-022-10475-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 3 |b 23 |c 06 |h 1141-1162 | ||